Back to Top Skip to main content the official website of the Military Health System (MHS) and the Defense Health Agency (DHA)

Utility Navigation Links

TRICARE Policy Manual 6010.63-M, April 2021
Chapter 4
Section 5.4
Reduction Mammaplasty For Macromastia
Issue Date:  October 22, 1985
Authority:  32 CFR 199.4(c)(2) and (e)(8)
Copyright:  CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.
2.1  Reduction mammaplasty is the surgical excision of a substantial portion of the breast, including the skin and the underlying glandular tissue, until a clinically normal size is obtained. Because breasts are paired organs and macromastia usually affects both sides, bilateral surgery is performed. When there is significant one-sided hypertrophy, a unilateral breast reduction is performed. Reduction mammaplasty is usually prompted by physical necessity due to the signs and symptoms of macromastia, and is, therefore, reconstructive in nature.
2.2  Female breast hypertrophy, macromastia, is the development of abnormally large breasts. This condition can cause significant clinical manifestations when the excessive breast weight adversely affect the supporting structures of the shoulders, neck, and trunk. Macromastia is distinguished from large, normal breast by the presence of persistent, painful symptoms and physical signs.
Note:  There are wide variations in the range of normal individual height, body weight and associated breast sizes; the amount of breast tissue that must be removed to relieve symptoms therefore varies with the height and weight of each patient (e.g., a small-statured person will need proportionally less breast tissue removed to alleviate signs and symptoms of macromastia than a larger person). Guidelines for determining whether breast reduction is medically necessary include the Schnur sliding scale [Schnur, Paul L, et al, “Reduction Mammaplasty: Cosmetic or Reconstructive Procedure?” Annals of Plastic Surgery, September 1991; 27 (3): 232-7] and InterQual guidelines.
3.1  Reduction mammaplasty is covered when signs and symptoms of macromastia are functionally significant.
Note:  Symptoms may include postural backache, upper back and neck pain, and ulnar paresthesia. Appropriate physical findings are “true” hypertrophy, and shoulder grooving and intertrigo. Signs may include poor posture and the inability to participate in normal physical activities. These may be functionally significant in some individuals.
3.2  Photo-documentation may be requested as part of a coverage determination.
4.1  Reduction mammaplasties solely to treat fibrocystic disease of the breast.
4.2  Reduction mammaplasty performed solely for cosmetic purposes.
4.3  Mastopexy surgery.
- END -

Utility Navigation Links

DoD Seal is the official website of the Defense Health Agency (DHA) a component of the Military Health System

TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

If you have a question regarding TRICARE benefits, please go to the TRICARE Contact Us page page.
If you need help with technical/operational issues, please go to the TRICARE Manuals Online Help page.

The appearance of hyperlinks to external websites does not constitute endorsement by the DHA of these websites or the information, products or services contained therein. For other than authorized government activities, the DHA does not exercise any editorial control over the information you may find at other locations. Such links are provided consistent with the stated purpose of this DoD website.


DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.